A Pilot Study of NY-ESO-1ᶜ²⁵⁹T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma

Trial Profile

A Pilot Study of NY-ESO-1ᶜ²⁵⁹T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs NY-ESO-1c259 TCR-transduced lymphocytes (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Liposarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 05 Jun 2017 According to an Adaptimmune Therapeutics media release, as of May 18, 2017, 3 subjects have been enrolled in the study.
    • 05 Jun 2017 According to an Adaptimmune Therapeutics media release, trial design has been presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top